Challenges in SEC Protein Analyses: Are Platform Methods Possible?

Size Exclusion Chromatography (SEC) has been widely used for the accurate determination of protein aggregate, monomer, and small sized fragments in monoclonal antibodies, antibody drug conjugates, bi-specifics and fusion proteins used as biotherapeutics and other end use applications. While SEC is intended to separate molecules based on their size in solution, non-desired secondary interactions can hinder the ability to quickly develop an acceptable separation due to the need to evaluate different SEC eluents, that may contain co-solvents or additives.

This technical seminar will detail how synergistic advancements in SEC column hardware and particle technology work to minimize secondary ionic or hydrophobic interactions between proteins and the column to allow chromatographers to use a generic or platform method for size based separations of different protein samples.

Presenter: Bill Warren (Principal Product Manager, Waters Corporation)

Bill received his Masters in Microbiology and Immunology from University of Louisville School of Medicine. In 1986, joined Waters Corporation as an senior applications chemist involved with the research and development of HPLC, FPLC, and Capillary Electrophoresis applications for the analysis and purification of proteins, peptides, and nucleic acids. Following four years as a field based technical sales representative for Waters, Bill enjoyed a tenure as Manager, Core Product Evaluation Laboratory within the Waters Worldwide Marketing Organization. Bill currently is a Principal Bioseparation Columns Product Manager whose responsibilities involve assisting in the development and commercialization of innovative reagents and chromatography-based technologies for the separation, purification, and characterization of biological molecules.